期刊
FEBS LETTERS
卷 588, 期 2, 页码 269-277出版社
WILEY
DOI: 10.1016/j.febslet.2013.11.029
关键词
Protein engineering; Antibody therapeutics; Protein aggregation; Stability
Human monoclonal antibodies often display limited thermodynamic and colloidal stabilities. This behavior hinders their production, and places limitations on the development of novel formulation conditions and therapeutic applications. Antibodies are highly diverse molecules, with much of the sequence variation observed within variable domain families and, in particular, their complementarity determining regions. This has complicated the development of comprehensive strategies for the stability engineering of the human antibody repertoire. Here we provide an overview of the field, and discuss recent advances in the development of robust and aggregation resistant antibody therapeutics. Crown Copyright (C) 2013 Published by Elsevier B. V. on behalf of Federation of European Biochemical Society. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据